Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer

التفاصيل البيبلوغرافية
العنوان: Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer
المؤلفون: Jgm Bonfrèr, E Hamersma-v.d. Linden, E. Engelsman, W Nooyen, Peter F. Bruning, M. de Jong-Bakker
المصدر: Breast Cancer Research and Treatment. 4:289-295
بيانات النشر: Springer Science and Business Media LLC, 1984.
سنة النشر: 1984
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Hydrocortisone, Thyrotropin, Breast Neoplasms, Drug withdrawal, Breast cancer, Internal medicine, medicine, Humans, business.industry, Primary hypothyroidism, Cancer, Middle Aged, medicine.disease, Aminoglutethimide, Surgery, Clinical trial, Oncology, Toxicity, Female, Menopause, business, medicine.drug
الوصف: In a phase II clinical trial, 38 postmenopausal women with advanced breast cancer were treated with aminoglutethimide and replacement hydrocortisone. All women had previously received up to 4 modalities of endocrine therapy. Seventeen patients had also been treated with cytostatic drugs. Twenty-five percent of the 29 evaluable patients experienced objective tumor regression, lasting from 11 to more than 18 months. In 29% the disease was stabilized for 3 to more than 15 months. Toxicity was significant, necessitating drug withdrawal in 3 patients. One patient died within 3 weeks of therapy from multiple perforated gastric ulcers. Two patients developed herpes zoster within 4 weeks of treatment. Many side effects were minor and transient. However, treatment resulted in overt primary hypothyroidism in 25% of the evaluable patients and in a strongly increased need of acenocoumarin in all 3 patients on anticoagulant therapy.
تدمد: 1573-7217
0167-6806
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::706a2be4c856d2a37c608fdc831db3e6
https://doi.org/10.1007/bf01806041
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....706a2be4c856d2a37c608fdc831db3e6
قاعدة البيانات: OpenAIRE